Royalty payment

DGAP-News: MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma

Retrieved on: 
Friday, July 16, 2021

The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.

Key Points: 
  • The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.
  • "We're pleased that Royalty Pharma is taking an equity position in MorphoSys as part of the long-term strategic finance partnership the two companies entered into this year," said Sung Lee, Chief Financial Officer of MorphoSys.
  • The new MorphoSys shares will be listed on the Frankfurt Stock Exchange.
  • Royalty Pharma has agreed, subject to limited exceptions, not to sell or otherwise transfer any of the new ordinary shares for a period of twelve months.

Royalty Pharma Declares Third-Quarter 2021 Dividend

Retrieved on: 
Friday, July 16, 2021

NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share.

Key Points: 
  • NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share.
  • The dividend will be paid on September 15, 2021, to shareholders of record at the close of business on August 20, 2021.
  • Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update

Retrieved on: 
Friday, July 16, 2021

The number of prescriptions1 for VYZULTA in the U.S. increased by 21% in the second quarter of 2021 compared to the second quarter of 2020.

Key Points: 
  • The number of prescriptions1 for VYZULTA in the U.S. increased by 21% in the second quarter of 2021 compared to the second quarter of 2020.
  • The number of ZERVIATE U.S. prescriptions1 increased by 712% in the second quarter of 2021 over the second quarter of 2020.
  • Net revenue2 for the second quarter of 2021 was 0.7 million (including 0.6 million of net royalty payments).
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

Retrieved on: 
Thursday, July 15, 2021

Royalty Pharma intends to use the net proceeds from the 2051 Notes for general corporate purposes.

Key Points: 
  • Royalty Pharma intends to use the net proceeds from the 2051 Notes for general corporate purposes.
  • Royalty Pharma has developed a Social Bond Framework aligned with the International Capital Market Associations Social Bond Principles, 2021, which are voluntary guidelines that promote transparency and integrity in the social bond market.
  • ISS ESG has reviewed that Royalty Pharmas Social Bond Framework aligns with the Social Bond Principles issued by the International Capital Markets Association.
  • We are pleased to announce the pricing of our first ever Social Bond, underscoring our strong commitment to corporate social responsibility, stated Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma.

Barrick On Course to Achieve 2021 Production Targets

Retrieved on: 
Thursday, July 15, 2021

C1 cash costs per pound excludes royalties and production taxes and non-routine charges as they are not direct production costs.

Key Points: 
  • C1 cash costs per pound excludes royalties and production taxes and non-routine charges as they are not direct production costs.
  • Barrick will provide a full reconciliation of these non-GAAP financial measures when the Company reports its quarterly results on August9, 2021.
  • Barrick will provide additional discussion and analysis and other important information about its second quarter production levels and sales and associated costs when it reports actual results on August9, 2021.
  • Barrick also cautions that its 2021 guidance may be impacted by the unprecedented business and social disruption caused by the spread of Covid-19.

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

Retrieved on: 
Thursday, July 15, 2021

Kuros will receive an initial payment of $7 million from XOMA.

Key Points: 
  • Kuros will receive an initial payment of $7 million from XOMA.
  • In addition, Kuros retains the potential to receive up to $24 million in pre-commercial milestones from Checkmate, and is eligible to receive up to $142.5 million in sales milestones from Xoma.
  • Checkmate is conducting multiple clinical trials, including two phase 2 trials in the melanoma indication, which have already triggered two milestone payments of $2 and $4 million by Checkmate earlier this year.
  • These milestone payments together with the payment from the royalty purchase agreement announced today amount to $13 million in revenue to Kuros in 2021.

Verde Bio Holdings, Inc. Announces Opportunistic Divestiture of Assets

Retrieved on: 
Thursday, July 15, 2021

Verde Bio Holdings will achieve approximately 84 percent profit after holding this asset for a little more than three months.

Key Points: 
  • Verde Bio Holdings will achieve approximately 84 percent profit after holding this asset for a little more than three months.
  • In addition to the profits from sale, Verde also will receive all revenue of the assets related to production from the wells from March 1, 2021, to July 31, 2021, estimated to be approximately $80,000.
  • We are going to be opportunistic for our shareholders when the situation, such as this, necessitates it.
  • About Verde Bio Holdings, Inc.: Verde Bio Holdings, Inc. (OTC: VBHI), is a U.S. Energy Company based in Frisco, Texas, engaged in the acquisition and management of Mineral and Royalty interests in lower risk, onshore oil and gas properties within the major oil and gas plays in the U.S.

XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

Retrieved on: 
Thursday, July 15, 2021

We were drawn to vidutolimod because of the breadth of Checkmates development activities, said Jim Neal, Chief Executive Officer at XOMA.

Key Points: 
  • We were drawn to vidutolimod because of the breadth of Checkmates development activities, said Jim Neal, Chief Executive Officer at XOMA.
  • Kuros will be eligible to receive certain sales milestone payments from XOMA based on net sales of vidutolimod.
  • XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.
  • As of the date of this press release, all assets in XOMAs milestone and royalty portfolio, including vidutolimod, are investigational compounds.

Music Industry Experts Form Exclusive Alliance to Capture Global Royalty Revenue for Advertisers

Retrieved on: 
Tuesday, July 13, 2021

LOS ANGELES, and LONDON, July 13, 2021 /PRNewswire/ -- Today the music & concert tour industry's payroll powerhouse and the leader in music publishing administration technology & rights intelligence have formed an exclusive alliance for maximizing royalty revenue for North American and Global advertisers.

Key Points: 
  • LOS ANGELES, and LONDON, July 13, 2021 /PRNewswire/ -- Today the music & concert tour industry's payroll powerhouse and the leader in music publishing administration technology & rights intelligence have formed an exclusive alliance for maximizing royalty revenue for North American and Global advertisers.
  • Marketers aware of this royalty revenue stream often rely on music publishing administrators who do not have robust tracking technology or global data intelligence to deliver optimal royalty collection.
  • Together Melos and The TEAM Companies (TTC) offer the most comprehensive solution for global music publishing administration in the ad industry.
  • The more revenue we capture, the more advertisers can utilize it for future productions," added Richard Cottrell, CEO of Melos.

SoundExchange Announces Expansion into Private Copy Royalty Collection and Distribution

Retrieved on: 
Tuesday, July 13, 2021

"We are committed to leveraging our best-in-class technology solutions to enhance the music ecosystem," said Michael Huppe, President & CEO, SoundExchange.

Key Points: 
  • "We are committed to leveraging our best-in-class technology solutions to enhance the music ecosystem," said Michael Huppe, President & CEO, SoundExchange.
  • "Expanding into private copy royalty collection and distribution is just one step in our mission to make the business of music simpler and more efficient for creators."
  • SoundExchange plans to begin claiming international PC royalties in late 2021 and domestic PC royalties in February 2022.
  • AARC will distribute all available royalties it has collected since 2018 in a final distribution in late 2021 before it ceases operations.